Cardiff Oncology, Inc. (CRDF): R&D Expense
$35.33M
Year ended 2025-12-31
$25.95M
Trailing 12 months to 2026-06-30
+9.2%
3-year compound annual growth
+25.8%
5-year compound annual growth
+12.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.33M | -4.1% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $36.85M | +12.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $32.86M | +21.2% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $27.11M | +56.0% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $17.38M | +54.7% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $11.23M | +0.7% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $11.16M | +36.7% | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | $8.16M | +3.6% | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | $7.88M | -47.5% | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | $15.01M | +41.7% | 2018-02-26, From 2016-01-01 |
| 2015-12-31 | $10.59M | +59.0% | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | $6.66M | +68.8% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $3.95M | +105.6% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $1.92M | +110.9% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $910.7K | n/a | 2014-03-17, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $28.52M | -11.2% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
| Pluri Inc. (PLUR) | 2026-06-30 | $15.09M | +17.4% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗